CN108342355B - 原始卵泡激活剂及其在人卵巢皮质培养液中的应用 - Google Patents
原始卵泡激活剂及其在人卵巢皮质培养液中的应用 Download PDFInfo
- Publication number
- CN108342355B CN108342355B CN201810023690.0A CN201810023690A CN108342355B CN 108342355 B CN108342355 B CN 108342355B CN 201810023690 A CN201810023690 A CN 201810023690A CN 108342355 B CN108342355 B CN 108342355B
- Authority
- CN
- China
- Prior art keywords
- culture solution
- reagent
- activator
- human ovarian
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000002611 ovarian Effects 0.000 title claims abstract description 54
- 230000003213 activating effect Effects 0.000 title description 8
- 239000012190 activator Substances 0.000 claims abstract description 62
- 230000019491 signal transduction Effects 0.000 claims abstract description 41
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 claims abstract description 28
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 claims abstract description 28
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 claims abstract description 25
- 108091007960 PI3Ks Proteins 0.000 claims abstract description 25
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 claims abstract description 19
- 210000001672 ovary Anatomy 0.000 claims description 51
- 239000003153 chemical reaction reagent Substances 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 14
- 238000004113 cell culture Methods 0.000 claims description 8
- 238000012258 culturing Methods 0.000 claims description 6
- 239000007640 basal medium Substances 0.000 claims description 4
- 238000004090 dissolution Methods 0.000 claims 2
- 238000011161 development Methods 0.000 abstract description 24
- 230000004913 activation Effects 0.000 abstract description 22
- 238000000338 in vitro Methods 0.000 abstract description 18
- 208000002500 Primary Ovarian Insufficiency Diseases 0.000 abstract description 5
- 206010036601 premature menopause Diseases 0.000 abstract description 5
- 208000017942 premature ovarian failure 1 Diseases 0.000 abstract description 4
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 52
- 241000699666 Mus <mouse, genus> Species 0.000 description 25
- 210000001519 tissue Anatomy 0.000 description 25
- 230000018109 developmental process Effects 0.000 description 23
- 238000001994 activation Methods 0.000 description 22
- 210000004681 ovum Anatomy 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 8
- 210000003734 kidney Anatomy 0.000 description 8
- 210000001161 mammalian embryo Anatomy 0.000 description 8
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 7
- 230000004720 fertilization Effects 0.000 description 7
- 210000000287 oocyte Anatomy 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 210000002503 granulosa cell Anatomy 0.000 description 6
- 229940088597 hormone Drugs 0.000 description 6
- 239000005556 hormone Substances 0.000 description 6
- 230000013020 embryo development Effects 0.000 description 5
- 239000003102 growth factor Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 4
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 4
- 102000008100 Human Serum Albumin Human genes 0.000 description 4
- 108091006905 Human Serum Albumin Proteins 0.000 description 4
- 206010042573 Superovulation Diseases 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 229940054269 sodium pyruvate Drugs 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 102000006771 Gonadotropins Human genes 0.000 description 3
- 108010086677 Gonadotropins Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 230000003698 anagen phase Effects 0.000 description 3
- 230000002146 bilateral effect Effects 0.000 description 3
- 230000003325 follicular Effects 0.000 description 3
- 239000002622 gonadotropin Substances 0.000 description 3
- 210000003016 hypothalamus Anatomy 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000000877 morphologic effect Effects 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000001850 reproductive effect Effects 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- AGJBKFAPBKOEGA-UHFFFAOYSA-M 2-methoxyethylmercury(1+);acetate Chemical compound COCC[Hg]OC(C)=O AGJBKFAPBKOEGA-UHFFFAOYSA-M 0.000 description 2
- 101100093804 Caenorhabditis elegans rps-6 gene Proteins 0.000 description 2
- 108050006400 Cyclin Proteins 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102000009339 Proliferating Cell Nuclear Antigen Human genes 0.000 description 2
- 101150079271 RPS6 gene Proteins 0.000 description 2
- 101100254874 Schizosaccharomyces pombe (strain 972 / ATCC 24843) rps601 gene Proteins 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 230000008217 follicular development Effects 0.000 description 2
- 229940094892 gonadotropins Drugs 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 230000009245 menopause Effects 0.000 description 2
- 239000007758 minimum essential medium Substances 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- 210000002394 ovarian follicle Anatomy 0.000 description 2
- 230000011599 ovarian follicle development Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- DCWXELXMIBXGTH-QMMMGPOBSA-N phosphonotyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-QMMMGPOBSA-N 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 101150085492 rpsF gene Proteins 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000004231 tunica media Anatomy 0.000 description 2
- MHUWZNTUIIFHAS-DSSVUWSHSA-N 1,2-dioleoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC MHUWZNTUIIFHAS-DSSVUWSHSA-N 0.000 description 1
- JCAISGGAOQXEHJ-ZPFDUUQYSA-N Arg-Gln-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCN=C(N)N)N JCAISGGAOQXEHJ-ZPFDUUQYSA-N 0.000 description 1
- NYDIVDKTULRINZ-AVGNSLFASA-N Arg-Met-Lys Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N NYDIVDKTULRINZ-AVGNSLFASA-N 0.000 description 1
- IOXWDLNHXZOXQP-FXQIFTODSA-N Asp-Met-Ser Chemical compound CSCC[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CC(=O)O)N IOXWDLNHXZOXQP-FXQIFTODSA-N 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- IHDKKJVBLGXLEL-STQMWFEESA-N Gly-Tyr-Met Chemical compound CSCC[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)CN)C(O)=O IHDKKJVBLGXLEL-STQMWFEESA-N 0.000 description 1
- GFWLIJDQILOEPP-HSCHXYMDSA-N Lys-Ile-Trp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CCCCN)N GFWLIJDQILOEPP-HSCHXYMDSA-N 0.000 description 1
- 208000012266 Needlestick injury Diseases 0.000 description 1
- UMKYAYXCMYYNHI-AVGNSLFASA-N Phe-Gln-Asn Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)O)N UMKYAYXCMYYNHI-AVGNSLFASA-N 0.000 description 1
- BNFVPSRLHHPQKS-WHFBIAKZSA-N Ser-Asp-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O BNFVPSRLHHPQKS-WHFBIAKZSA-N 0.000 description 1
- UUIYFDAWNBSWPG-IHPCNDPISA-N Trp-Lys-Lys Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)O)N UUIYFDAWNBSWPG-IHPCNDPISA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 230000029849 luteinization Effects 0.000 description 1
- 108010043322 lysyl-tryptophyl-alpha-lysine Proteins 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000010413 mother solution Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 230000000624 ovulatory effect Effects 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 210000003684 theca cell Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
- C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases [EC 2.]
- C12N2501/727—Kinases (EC 2.7.)
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Reproductive Health (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
MII | 2细胞胚胎 | (%) | 2细胞胚胎 | 成活仔数 | (%) | |
处理组卵 | 90 | 66 | 73.33 | 45 | 11 | 24.4 |
超排卵 | 178 | 160 | 89.89 | 45 | 14 | 31.1 |
Claims (2)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810023690.0A CN108342355B (zh) | 2018-01-10 | 2018-01-10 | 原始卵泡激活剂及其在人卵巢皮质培养液中的应用 |
PCT/IB2018/052447 WO2019138268A1 (zh) | 2018-01-10 | 2018-04-09 | 原始卵泡激活剂及其在人卵巢皮质培养液中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810023690.0A CN108342355B (zh) | 2018-01-10 | 2018-01-10 | 原始卵泡激活剂及其在人卵巢皮质培养液中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108342355A CN108342355A (zh) | 2018-07-31 |
CN108342355B true CN108342355B (zh) | 2021-06-18 |
Family
ID=62960689
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810023690.0A Expired - Fee Related CN108342355B (zh) | 2018-01-10 | 2018-01-10 | 原始卵泡激活剂及其在人卵巢皮质培养液中的应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN108342355B (zh) |
WO (1) | WO2019138268A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109439618A (zh) * | 2018-11-01 | 2019-03-08 | 多能干细胞再生医学科技(广州)有限公司 | 一种激活增多卵泡的制剂及其应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009089366A2 (en) * | 2008-01-08 | 2009-07-16 | The Johns Hopkins University | Suppression of cancer growth and metastasis using nordihydroguaiaretic acid derivatives with metabolic modulators |
CN102533642A (zh) * | 2011-11-28 | 2012-07-04 | 李晶 | 原始卵泡体外激活试剂盒 |
CN103387960A (zh) * | 2013-07-22 | 2013-11-13 | 南京医科大学 | mTOR信号通路激活剂及其在原始卵泡体外激活中的应用 |
CN104130972A (zh) * | 2014-07-09 | 2014-11-05 | 南京医科大学 | 原始卵泡激活剂及其应用 |
CN106636368A (zh) * | 2016-11-28 | 2017-05-10 | 山东大学 | miR‑130a 在卵巢癌的诊断、治疗及预后中的应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100191040A1 (en) * | 2009-01-23 | 2010-07-29 | The Board Of Trustees Of The Leland Stanford Junior University | Manipulation of ovarian primordial follicles |
TW201526894A (zh) * | 2013-04-17 | 2015-07-16 | Signal Pharm Llc | 藉二氫吡并吡治療癌症 |
-
2018
- 2018-01-10 CN CN201810023690.0A patent/CN108342355B/zh not_active Expired - Fee Related
- 2018-04-09 WO PCT/IB2018/052447 patent/WO2019138268A1/zh active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009089366A2 (en) * | 2008-01-08 | 2009-07-16 | The Johns Hopkins University | Suppression of cancer growth and metastasis using nordihydroguaiaretic acid derivatives with metabolic modulators |
CN102533642A (zh) * | 2011-11-28 | 2012-07-04 | 李晶 | 原始卵泡体外激活试剂盒 |
CN103387960A (zh) * | 2013-07-22 | 2013-11-13 | 南京医科大学 | mTOR信号通路激活剂及其在原始卵泡体外激活中的应用 |
CN104130972A (zh) * | 2014-07-09 | 2014-11-05 | 南京医科大学 | 原始卵泡激活剂及其应用 |
CN106636368A (zh) * | 2016-11-28 | 2017-05-10 | 山东大学 | miR‑130a 在卵巢癌的诊断、治疗及预后中的应用 |
Non-Patent Citations (3)
Title |
---|
Attempted application of bioengineered/biosynthetic supporting matrices with phosphatidylinositol-trisphosphate-enhancing substances to organ culture of human primordial follicles;Galit Lerer-Serfaty et al.;《J Assist Reprod Genet》;20130811;第30卷;第1279-1288页 * |
New strategy for in vitro activation of primordial follicles with mTOR and PI3K stimulators;Xinhui Sun et al.;《Cell Cycle》;20150301;第14卷(第5期);第721-731页 * |
针刺治疗对卵巢早衰大鼠PI3K/Akt/mTOR信号通路的影响;张毅敏等;《中国针灸》;20150131;第35卷(第1期);第53-58页 * |
Also Published As
Publication number | Publication date |
---|---|
CN108342355A (zh) | 2018-07-31 |
WO2019138268A1 (zh) | 2019-07-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Lopata et al. | In vitro fertilization of preovulatory oocytes and embryo transfer in infertile patients treated with clomiphene and human chorionic gonadotropin | |
Oehninger et al. | Intracytoplasmic sperm injection: achievement of high pregnancy rates in couples with severe male factor infertility is dependent primarily upon female and not male factors | |
Bustillo et al. | Nonsurgical ovum transfer as a treatment in infertile women: preliminary experience | |
Leung et al. | Serum supplement in human in vitro fertilization and embryo development | |
ES2286008T3 (es) | Tratamiento de la infertilidad. | |
JPH06508527A (ja) | 長期培養に維持されたホルモン分泌細胞 | |
DE60025905T2 (de) | In vitro methode zur synchronisation von oozytenreifung | |
CN103387960B (zh) | mTOR信号通路激活剂及其在原始卵泡体外激活中的应用 | |
Weitlauf et al. | Influence of estrogen and progesterone on the incorporation of 35S methionine by blastocysts in ovariectomized mice | |
CN104130972B (zh) | 原始卵泡激活剂及其应用 | |
Kim et al. | Successful pregnancy and delivery after ICSI with artificial oocyte activation by calcium ionophore in in-vitro matured oocytes: a case report | |
PAULSON et al. | In vitro fertilization in unstimulated cycles: a clinical trial using hCG for timing of follicle aspiration | |
Brück et al. | Repeated transvaginal oocyte aspiration in unstimulated and FSH-treated mares | |
CN108342355B (zh) | 原始卵泡激活剂及其在人卵巢皮质培养液中的应用 | |
CN102533642B (zh) | 原始卵泡体外激活试剂盒 | |
Thompson et al. | Experimental pituitary basophilism | |
Son et al. | Successful birth after transfer of blastocysts derived from oocytes of unstimulated woman with regular menstrual cycle after IVM approach | |
AU2020104306B4 (en) | Method for enhancing assisted breeding techniques | |
RU2617042C2 (ru) | Способ индукции суперовуляции у коров-доноров эмбрионов с пролонгированием действия гипофизарных гонадотропинов | |
CN112807296B (zh) | 琥珀酸在诊断或治疗自然流产中的应用 | |
RU2633079C2 (ru) | Фармацевтическая композиция с пролонгированным действием гонадотропинов для проведения индукции суперовуляции у самок млекопитающих | |
Richards | Sperm induced signalling events in the cells of the female reproductive tract | |
Sumar et al. | Embryo transfer | |
Levine | Luteal support with Crinone 8% in 1827 women undergoing assisted reproductive technology (ART) procedures | |
Ishikawa-Yamauchi | Functional role of the oviduct in mammalian fertilization |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210910 Address after: 210000 No. 199 shogundong Road, Gulou District, Nanjing, Jiangsu Patentee after: Nanjing Ivy Kangtai Biotechnology Co.,Ltd. Address before: 210061 east side of 5 / F, building e, phase II, Zhongdan Ecological Life Science Industrial Park, no.3-1, xinjinhu Road, high tech Development Zone, Nanjing City, Jiangsu Province Patentee before: OVAHEALTH BIOTECHNOLOGY Co.,Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20210618 Termination date: 20220110 |